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Infective endocarditis and intravenous drug use: 
an observational study.
Intravenous drug use (IVDU) is a recognised predisposition for the
development of infective endocarditis (IE). The incidence of IE is
increasing in the UK and globally1,2, and the aetiology has shifted
with an increase in IVDU3. The UK has the highest rates of IVDU
in Europe2.
Previous studies of surgery in this group have been of variable
size and the duration of follow-up has often been short4-6. These
studies have mainly compared outcomes in IVDUs with non-
IVDUs.
The European Society of Cardiology (ESC) guidelines defines the
following as Class I indications for surgery for left sided disease
as7:
Heart failure
Aortic or mitral valve IE causing severe
regurgitation/obstruction/fistulation.
Leading to either refractory pulmonary oedema, cardiogenic
shock, symptoms of heart failure or echocardiographic evidence
of poor haemodynamic tolerance
Uncontrolled infection
Locally uncontrolled infection, such as abscess, fistula, enlarging
vegetation or false aneurysm.
Infection caused by fungi or multi-resistant organism.
Prevention of embolism
Aortic/mitral IE with persistent vegetation >10mm after
one/more embolic episodes during appropriate antimicrobial
therapy.
In clinical practice, these indications are extrapolated to the right
heart to justify surgery where pulmonary embolization or severe
regurgitation occurs.
Background
Despite ESC guidelines being clear on Class I indications for
surgery7, poor compliance with medical therapy, poor long-term
outcomes in this sub-group as well as re-infection risks associated
with ongoing IVDU are concerns that can delay surgery6,8.
A particular problem is encountered when patients who have had
valve surgery re-present with a second episode of endocarditis
which has resulted from continued drug use.
Controversy
We aim to describe the characteristics, complications and
outcomes of IVDUs with IE reviewed by the local endocarditis
team at the Leeds Teaching Hospitals NHS Trust (LTHT) over more
than a decade.
The focus is to understand the role of surgery for IE in IVDUs and
how this affects outcomes for these patients, and whether re-
infection rates and long-term outcomes should influence
decision making regarding surgery.
Aims
This study was submitted to the Research and Innovation
Department at LTHT. It was regarded as a service evaluation and
therefore did not require specific ethical approval or patient
consent providing usual data protection was in place.
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Consecutive patients admitted between 01/01/06 and 31/12/16
referred to the local endocarditis team with suspected IE were
eligible for inclusion.
Inclusion in the study was dependent on the modified Duke
criteria. For an episode to be eligible we required:
! Duke definite
OR
! Duke possible and treated by the local endocarditis team as IE
AND
! Predisposing IVDU (within 90 days)
Patients
This dataset was derived from a local database of all cases
referred to the local endocarditis team. For each patient the
written medical record was reviewed alongside local electronic
patient records.
The following information was obtained:
Patient characteristics
! Age
! Sex
! Severity of illness (qSOFA score on admission)
IE variables
! Affected structures
! Microorganisms (blood and cultures of excised valves)
Complications
! Heart failure (peripheral or pulmonary congestion, with
echocardiographic evidence of haemodynamic dysfunction)
! Embolisation
! Abscess formation
Surgery
! Type of operation(s)
! Number of operations
! Indication for operation.
Data collection
Reinfection
! Relapse – reinfection with same pathogen within 1-year
! Recurrence – reinfection with different pathogen OR reinfection
with same isolate beyond 1-year
Repeat surgery
All-cause mortality
Outcomes
Microorganisms
! Staph. aureus was the most common pathogen and occurred
in 57.8% of episodes.
! 7 episode were culture negative
! 7 episodes involved two pathogens
Affected structures
Operated
(n=49)
Non-
operated
(n=43)
p value
Age (years) 37.2 (8.3) 36.1 (8.7) 0.53
Male sex 31 (70.5) 33 (70.2) 1.00
S. aureus 23 (52.3) 30 (63.8) 0.37
Left sided 28 (63.6) 20 (42.6)
<0.001
Right sided 6 (13.6) 24 (51.1)
Both 10 (22.7) 3 (6.4)
qSOFA > 2 5 (13.9) 7 (17.9) 0.87
During the study period there were:
! 109 episodes
! 92 patients
! 95 episodes Duke definite
! 14 episodes Duke possible and treated for IE
49 patients (53.3%) underwent surgery. In all cases there was a
Class I indication for surgery.
Implantation of bioprosthetic valves for left-sided disease was
the most common intervention. Intervention on right sided
structures was uncommon. There was one abandoned attempt
at pulmonary valve replacement.
Only one patient underwent a second operation during the study
period due to late recurrence with S. epidermidis.
There were no significant differences in the pre-specified
characteristics of those who were operated on compared to non-
operated except a preponderance of left-sided disease (table 1).
Surgery
Survival
! Recurrence rate 13.0%
! Relapse rate 3.26%
In this group outcomes were poor,. At follow-up 8 had died. The
causes of death were heart failure (3), sepsis (3), stroke (1) and
bronchopneumonia(1). The clinical state of the patient often
meant that they were unsuitable for repeat surgery when this
might have been considered.
Cardiac re-infection
Discussion
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Culture negative
Others
Candida spp.
Pseudomonas spp.
Enterococcus spp.
Strep. angionosis group
Oral Strep.
Beta-haemolytic Strep.
Coagulase negative Staph.
Staph. aureus
Episodes
IE affected left-sided structures more than right.
Complications
Other emboli included: renal, mesenteric, endophthalmitis, upper
and lower limbs.
Significant complications were common in this cohort and
occurred in 68.8% of episodes. These were discussed at the
cardiac surgery MDT for their suitability for operation.
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Aortic root abscess
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In the operated group, short term mortality was low. However,
this was not translated into long term survival. The survival in
the surgical group was <30% at 10 years (figure 6).
In regression analysis the odds of mortality were increased with
surgery, qSOFA >2 and were lower with right sided infection
(table 2).
The design was an observational study based on a prospectively
collected database.
Contrary to common perception, IE affected left-sided structures
more commonly than right. There may have been inclusion bias
as LTHT receives patients from local hospitals, most of whom
require surgery. However, our data are consistent with other
contemporary studies5,6.
Long-term survival following an episode of IE was low in this
cohort. Most of the deaths were unrelated to a further episode
of IE. When compared to the medically treated group, survival
was reduced in the surgical cohort. The reasons for this are not
immediately obvious but were not related to choice of
prosthesis. However, the survival curves were similar despite
surgery being indicated by significant complications.
30-day mortality and relapse rates were low which indicates that
we were mostly successful in treating the acute episodes. IVDU
patients are known to have significantly reduced life expectancy
compared to age and sex-matched controls9. The high all-cause
mortality which we report suggests that a proportion of patients
continue to lead a high-risk lifestyle. Continued IVDU after
completing treatment is a recognised problem. We did not
measure the rate of return to IVDU but a recent study found that
70% and 44% of patients returned to IVDU following a first and
second operation, respectively6.
The rate of cardiac re-infection was low but these patients had a
high mortality rate. In this patient group, those who might have
been eligible for re-operation were often too unwell to be
considered for surgery. There was a preference to treat
recurrent right-sided infection conservatively and these patients
survived.
Surgery was performed for Class 1 indications. It seems probable
that the majority of these patients would have died in the short-
term, if not operated on as a consequence of severe heart
failure, embolization or uncontrolled sepsis. Surgery was
successful in all but one episode but predicted life expectancy
was often not achieved.
Surgery can redress haemodynamic and embolic problems but it
is important to remember the need for an holistic approach in
managing this challenging patient group after they have
completed their acute treatment. We hypothesise that the
continued high mortality in this patient group is part of the
spectrum of complications related to chronic drug misuse.
Study design
On review of the medical records, the majority of deaths
occurred late and were unrelated to an episode of IE.
Compliance with anticoagulation is an important consideration,
however there was no evidence that this contributed to late
mortality (figure 7). Those offered mechanical valves in fact
faired better, but this relationship was not statically significant
and the numbers at risk were small.
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In 15 episodes more than one structure was involved. A
pacemaker infection occurred in one patient.
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Figure 1. Frequency of left and right sided episodes of IE
Figure 2. Frequency of structures affected during episodes of IE
Figure 5. Frequency of type of operation.
M, mechanical; B, bioprosthetic; AVR, aortic valve replacement; MVR, mitral valve 
replacement; TVR, tricuspid valve replacement; PVR, pulmonary valve replacement.
Figure 4. Frequency of complications.
Figure 3. Frequency of microorganisms identified..
Figure 6. Kaplan Meier survival curves for operated and non-operated groups.
Figure 7. Kaplan Meier survival curves for mechanical or bioprosthetic valves.
Table 1. Characteristics of operated compared to non-operated group
Table 2. Regression analysis of covariables and their association with mortality
1 year 3 years 5 years 10 years
Overall 73.6 61.9 58.7 43.4
Operated 68.2 52.5 46.3 29.3
Not operated 78.7 71.2 71.2 55.1
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